Dianthus Therapeutics Inc. (DNTH) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $53.11
• Market Cap: $2.24B
• EPS: $-3.50
• 52-Week High: $57.50
• 52-Week Low: $13.37

Market Sentiment

Dianthus Therapeutics Inc. currently has a Bullish sentiment score of 0.19.

About Dianthus Therapeutics Inc.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company based in New York dedicated to developing novel monoclonal antibody therapies for severe autoimmune and inflammatory diseases. The firm boasts a strong pipeline aimed at addressing significant unmet medical needs through its proprietary drug development programs. By advancing innovative solutions and progressing through critical clinical trials, Dianthus is positioning itself at the forefront of precision medicine, making i...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Dianthus Therapeutics Inc. and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does DNTH pay dividends?

Dianthus Therapeutics Inc. (DNTH) does not currently pay a regular dividend.

What is DNTH's market cap?

Dianthus Therapeutics Inc. (DNTH) has a market capitalization of $2.24B with a current stock price of $53.11.